The cost of Pluvicto can vary based on several factors, including your insurance coverage. Drug savings programs can also lower the price you’ll pay for Pluvicto. As with all medications ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of ...

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful radiographic progression-free survival benefit ...

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

Pluvicto (lutetium [177Lu] vipivotide tetraxetan), which won FDA approval in 2022, is fast becoming the dominant RLT for prostate cancer, according to GlobalData. The data and analysis firm wrote ...

Lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) received an expanded indication, which allows the radioligand therapy to be used after one androgen receptor pathway inhibitor (ARPI), as ...

The US Food and Drug Administration (FDA) has expanded the approval for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults with prostate-specific membrane antigen (PSMA ...

Pluvicto, a cutting-edge therapy, is designed to specifically target prostate-specific membrane antigen (PSMA+) cancer cells, delivering radiation directly to them while minimizing damage to ...

After a median follow-up of 20.9 months, patients on Pluvicto had radiographic progression-free survival (PFS) of 8.7 months, compared to 3.4 months in the control group, while overall survival ...

FCS now offers three FDA-approved drugs, Pluvicto™, Xofigo ® and LUTATHERA™ (Radium-223 dichloride), at 14 clinic sites across its statewide network with plans to add one more site in Wesley ...

The field is now looking to address patients that do not respond or progress after Pluvicto therapy. We believe ATNM-400 can address this high unmet need and we are incredibly excited by our data ...